Company intelligence / Profile preview

Surf Bio

Palo Alto, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Surf Bio has generated in-vitro and in-vivo data on safety and efficacy of its SnapShot™ polymer-based high-concentration biologic delivery platform, enabling high-dose subcutaneous administration of antibodies and biologics for diseases such as diabetes, cancer, and infectious diseases. The company is actively collaborating with global pharmaceutical partners, but has not disclosed clinical trial data to date.

Therapeutic areas: OncologyInfectious DiseasesEndocrinology
Modalities: Monoclonal antibodyBiologicGene therapyPolymer-drug conjugate therapy
Industry: Drug Discovery Services

Partnerships

Multiple ongoing collaborations with leading multinational pharmaceutical companies

Beyond the preview

Go deeper on Surf Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surf Bio.

Explore the full profile